换一批Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
第一作者：
D,Tsai
第一单位：
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.
作者：
医学主题词
抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗原, CD20(Antigens, CD20);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);B-淋巴细胞(B-Lymphocytes);综合疗法(Combined Modality Therapy);无病生存(Disease-Free Survival);女(雌)性(Female);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);免疫法, 被动(Immunization, Passive);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);淋巴瘤, 非霍奇金(Lymphoma, Non-Hodgkin);男(雄)性(Male);中年人(Middle Aged);挽救疗法(Salvage Therapy);移植, 自体(Transplantation, Autologous);治疗结果(Treatment Outcome)
DOI
10.1038/sj.bmt.1701944
PMID
10482937
发布时间
2022-03-09
- 浏览16
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
